Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Ariad Pharmaceuticals' Loss Shrinks 23% as Iclusig Revenue Rises

Controversial small-cap biopharmaceutical company Ariad Pharmaceuticals (NASDAQ: ARIA  ) took steps in the right direction to rebuilding its Iclusig brand this morning with the release of its first-quarter earnings results.

For the quarter, total revenue surged 82% to $11.8 million and included $8 million in sales of its leukemia drug Iclusig -- which was temporarily pulled from markets late last year for a couple of weeks and relabeled with more inclusive safety warnings – up 25% from the prior year. Per its press release, $4.7 million in sales came from the U.S. and $3.3 million from Europe. Ariad also noted $3.1 million in deferred revenue not yet reported, including $1.3 million in inventory waiting to be shipped from pharmacies to patients, and $1.8 million shipped to France despite the fact that reimbursement pricing negotiations are still ongoing.

In addition to product revenue, Ariad recorded $3.8 million in licensing revenue reflecting a $3.75 million milestone payment from Medinol for the licensing of ridaforolimus.

Research and development expenses shrank considerably during the quarter, partially as a result of the clinical hold placed on Iclusig by the FDA last year. R&D costs totaled just $28.6 million, down 31% from the prior-year period, as a reduction in clinical-trial costs, primarily the absence of its EPIC trial, which was shelved in October, led to the lower costs. Selling, general and administrative costs jumped 7% to $31.6 million and reflect the marketing effort put toward relaunching Iclusig at home and in new countries abroad.

Net loss for the quarter, inclusive of higher sales and lower costs, dipped 23% to $49.8 million, or $0.27 per share, from $64.7 million, or $0.36 per share in the year-ago period. Ariad announced that it ended the quarter with $183 million in cash and cash equivalents, down from $237.2 million in the sequential fourth quarter. 

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2947607, ~/Articles/ArticleHandler.aspx, 9/1/2015 10:20:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,125.88 -402.15 -2.43%
S&P 500 1,928.91 -43.27 -2.19%
NASD 4,682.52 -93.99 -1.97%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 10:03 AM
ARIA $9.28 Down -0.17 -1.75%
Ariad Pharmaceutic… CAPS Rating: ***